Actinium Pharmaceuticals, Inc. (ATNM)Healthcare | Biotechnology | New York, United States | NYSE American
1.30 USD
+0.05
(4.000%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 1.33 +0.03 (2.177%) ⇧ (April 17, 2026, 7:54 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ★★☆☆☆ |
Hot Take | April 18, 2026, 10:31 p.m. EDT
Actinium Pharmaceuticals is a pure binary biotech spec on a 2026 horizon with no near-term fundamental buy signal. While analyst sentiment is aggressive ('strong_buy') based on pipeline potential, the price action is flat and range-bound, and the statistical model predicts a defined downward drift in the next 45 days. The lack of put writing and the 'strong_buy' consensus masking negative earnings and massive cash burn suggest a 'buy the rumor' setup waiting for a catalyst that is months away, making it too volatile and fundamentally depleted for any meaningful allocation right now. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.131630 |
| AutoETS | 0.136312 |
| AutoTheta | 0.138023 |
| AutoARIMA | 0.205654 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 63% |
| H-stat | 1.77 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.553 |
| Excess Kurtosis | -0.54 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 21.624 |
| Revenue per Share | 0.003 |
| Market Cap | 40,787,492 |
| Forward P/E | -2.31 |
| Beta | -0.21 |
| Website | https://www.actiniumpharma.com |
As of April 18, 2026, 10:31 p.m. EDT: Options activity is dominated by long-term calls ($5.00 and $7.50 strikes) with significant open interest, suggesting a speculative bet on a multi-year catalyst (2026 manufacturing plans, AACR data) rather than near-term price appreciation. Trans-to-spot correlation in the short term is near zero (Ljung-Box p < 0.01), indicating a breakdown in short-term price trending capacity. Crucially, there is a complete absence of put options data (0 volume/0 OI), providing no downside hedging signal from speculators, which contrasts slightly with the mathematical forecast model predicting a -2.5% drift.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.08333337 |
| Address1 | 100 Park Avenue |
| Address2 | 23rd Floor |
| All Time High | 450.0 |
| All Time Low | 0.952 |
| Ask | 1.32 |
| Ask Size | 700 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 210,220 |
| Average Daily Volume3 Month | 135,990 |
| Average Volume | 135,990 |
| Average Volume10Days | 210,220 |
| Beta | -0.211 |
| Bid | 1.31 |
| Bid Size | 100 |
| Book Value | 0.251 |
| City | New York |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.3 |
| Current Ratio | 6.197 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 1.34 |
| Day Low | 1.25 |
| Debt To Equity | 21.624 |
| Display Name | Actinium Pharmaceuticals |
| Dividend Date | 1,597,104,000 |
| Earnings Timestamp End | 1,754,683,200 |
| Earnings Timestamp Start | 1,754,337,600 |
| Ebitda | -36,064,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.16 |
| Enterprise To Revenue | -64.17 |
| Enterprise Value | -5,775,266 |
| Eps Current Year | -0.88667 |
| Eps Forward | -0.56333 |
| Eps Trailing Twelve Months | -1.09 |
| Esg Populated | 0 |
| Exchange | ASE |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.1211 |
| Fifty Day Average Change | 0.1789 |
| Fifty Day Average Change Percent | 0.15957543 |
| Fifty Two Week Change Percent | 8.333338 |
| Fifty Two Week High | 1.945 |
| Fifty Two Week High Change | -0.6450001 |
| Fifty Two Week High Change Percent | -0.3316196 |
| Fifty Two Week Low | 0.952 |
| Fifty Two Week Low Change | 0.34799993 |
| Fifty Two Week Low Change Percent | 0.36554614 |
| Fifty Two Week Range | 0.952 - 1.945 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,356,618,600,000 |
| Float Shares | 30,838,625 |
| Forward Eps | -0.56333 |
| Forward P E | -2.3077059 |
| Free Cashflow | -12,849,375 |
| Full Exchange Name | NYSE American |
| Full Time Employees | 25 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 90,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0235 |
| Held Percent Institutions | 0.2057 |
| Implied Shares Outstanding | 31,374,994 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,597,104,000 |
| Last Split Factor | 1:30 |
| Long Business Summary | Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a preclinical non-prostate specific-membrane antigen targeting radiotherapy utilizing the Actinium-225 radioisotope for patients with prostate cancer. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York. |
| Long Name | Actinium Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 40,787,492 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_7845787 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -33,887,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 40,787,492 |
| Number Of Analyst Opinions | 4 |
| Open | 1.25 |
| Operating Cashflow | -24,580,000 |
| Operating Margins | -402.74445 |
| Payout Ratio | 0.0 |
| Phone | 646 677 3870 |
| Post Market Change | 0.028300047 |
| Post Market Change Percent | 2.1769269 |
| Post Market Price | 1.3283 |
| Post Market Time | 1,776,470,069 |
| Previous Close | 1.25 |
| Price Eps Current Year | -1.4661598 |
| Price Hint | 4 |
| Price To Book | 5.179283 |
| Price To Sales Trailing12 Months | 453.19437 |
| Profit Margins | 0.0 |
| Quick Ratio | 6.023 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.25 |
| Region | US |
| Regular Market Change | 0.05 |
| Regular Market Change Percent | 4.0 |
| Regular Market Day High | 1.34 |
| Regular Market Day Low | 1.25 |
| Regular Market Day Range | 1.25 - 1.34 |
| Regular Market Open | 1.25 |
| Regular Market Previous Close | 1.25 |
| Regular Market Price | 1.3 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 197,127 |
| Return On Assets | -0.35212 |
| Return On Equity | -1.6696401 |
| Revenue Per Share | 0.003 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 31,374,994 |
| Shares Percent Shares Out | 0.0404 |
| Shares Short | 1,267,895 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 1,066,143 |
| Short Name | Actinium Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.040700004 |
| Short Ratio | 10.57 |
| Source Interval | 15 |
| State | NY |
| Symbol | ATNM |
| Target High Price | 9.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 5.75 |
| Target Median Price | 5.0 |
| Total Cash | 47,998,000 |
| Total Cash Per Share | 1.54 |
| Total Debt | 1,694,000 |
| Total Revenue | 90,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.09 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.412475 |
| Two Hundred Day Average Change | -0.11247504 |
| Two Hundred Day Average Change Percent | -0.07962976 |
| Type Disp | Equity |
| Volume | 197,127 |
| Website | https://www.actiniumpharma.com |
| Zip | 10,017 |